This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Enoxolone
- DrugBank Accession Number
- DB13089
- Background
Enoxolone (glycyrrhetic acid) has been investigated for the basic science of Apparent Mineralocorticoid Excess (AME).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Enoxolone (DB13089)
- Weight
- Average: 470.694
Monoisotopic: 470.339609961 - Chemical Formula
- C30H46O4
- Synonyms
- Enoxolona
- Enoxolone
- Glycyrrhetic Acid
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Inflammation of mouth Combination Product in combination with: Chlorhexidine (DB00878), Benzocaine (DB01086) •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism ATyrosine-protein phosphatase non-receptor type 1 inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Enoxolone aluminum E3P03E2A65 4598-66-7 JIQUHOXNCWKESF-UBYPFOLZSA-K Enoxolone sodium E15REE98CW 2508-76-1 MOCOXAJEZKHXSF-IHMBCTQLSA-M Potassium glycyrrhetinate 5850KHR68O 85985-61-1 PWEZHTCCMJFGJY-IHMBCTQLSA-M - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ANZİBEL 5 MG/4 MG/3 MG EKİNEZYALI PASTİL, 20 ADET Enoxolone (3 mg) + Benzocaine (4 mg) + Chlorhexidine hydrochloride (5 mg) Lozenge Oral NOBEL İLAÇ SAN. VE TİC. A.Ş. 2015-05-14 Not applicable Turkey 
ANZİBEL 5 MG/4 MG/3 MG MEYANBALLI PASTİL, 20 ADET Enoxolone (3 mg) + Benzocaine (4 mg) + Chlorhexidine hydrochloride (5 mg) Lozenge Oral NOBEL İLAÇ SAN. VE TİC. A.Ş. 2015-05-13 Not applicable Turkey ANZİBEL 5 MG/4 MG/3 MG ZENCEFİLLİ PASTİL, 20 ADET Enoxolone (3 mg) + Benzocaine (4 mg) + Chlorhexidine hydrochloride (5 mg) Lozenge Oral NOBEL İLAÇ SAN. VE TİC. A.Ş. 2015-05-14 Not applicable Turkey Salonpas 30 Enoxolone (0.1 %) + Glycol salicylate (5 %) + Levomenthol (7 %) + alpha-Tocopherol acetate (2 %) Patch Topical Hisamitsu Pharmaceutical Malaysia Sdn. Bhd. 2020-09-08 Not applicable Malaysia 
Salonpas 30 Hot Enoxolone (0.1 %) + Capsicum (0.45 %) + Glycol salicylate (5 %) + Levomenthol (2 %) + alpha-Tocopherol acetate (2 %) Patch Topical Hisamitsu Pharmaceutical Malaysia Sdn. Bhd. 2020-09-08 Not applicable Malaysia
Categories
- ATC Codes
- D03AX10 — Enoxolone
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as triterpenoids. These are terpene molecules containing six isoprene units.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Triterpenoids
- Direct Parent
- Triterpenoids
- Alternative Parents
- Cyclohexenones / Secondary alcohols / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic homopolycyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Cyclic alcohol / Cyclohexenone / Hydrocarbon derivative / Ketone / Monocarboxylic acid or derivatives
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- hydroxy monocarboxylic acid, pentacyclic triterpenoid, cyclic terpene ketone (CHEBI:30853) / Oleananes (C02283) / Oleanane triterpenoids (LMPR0106150014)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P540XA09DR
- CAS number
- 471-53-4
- InChI Key
- MPDGHEJMBKOTSU-YKLVYJNSSA-N
- InChI
- InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21-,22-,23+,26+,27-,28-,29+,30+/m0/s1
- IUPAC Name
- (2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid
- SMILES
- [H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O
References
- General References
- TITCK Product Information: Anzibel (chlorhexidine/benzocaine/enoxolone) for oral use [Link]
- External Links
- PDB Entries
- 2w4q / 4pv5 / 5c71
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2, 3 Completed Basic Science Apparent Mineralocorticoid Excess (AME) 1 somestatus stop reason just information to hide 1, 2 Recruiting Diagnostic Unipolar Depression 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Lozenge Oral Patch Topical Cream Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00172 mg/mL ALOGPS logP 5.45 ALOGPS logP 6.03 Chemaxon logS -5.4 ALOGPS pKa (Strongest Acidic) 4.44 Chemaxon pKa (Strongest Basic) -0.84 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 74.6 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 134.27 m3·mol-1 Chemaxon Polarizability 55.22 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 224.7610796 predictedDarkChem Lite v0.1.0 [M-H]- 224.3409796 predictedDarkChem Lite v0.1.0 [M-H]- 209.5599 predictedDeepCCS 1.0 (2019) [M+H]+ 226.3040796 predictedDarkChem Lite v0.1.0 [M+H]+ 225.7173796 predictedDarkChem Lite v0.1.0 [M+H]+ 211.28871 predictedDeepCCS 1.0 (2019) [M+Na]+ 224.0340796 predictedDarkChem Lite v0.1.0 [M+Na]+ 217.40877 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Tyrosine-protein phosphatase which acts as a regulator of endoplasmic reticulum unfolded protein response. Mediates dephosphorylation of EIF2AK3/PERK; inactivating the protein kinase activity of EIF2AK3/PERK. May play an important role in CKII- and p60c-src-induced signal transduction cascades. May regulate the EFNA5-EPHA3 signaling pathway which modulates cell reorganization and cell-cell repulsion. May also regulate the hepatocyte growth factor receptor signaling pathway through dephosphorylation of MET
- Specific Function
- Cadherin binding
- Gene Name
- PTPN1
- Uniprot ID
- P18031
- Uniprot Name
- Tyrosine-protein phosphatase non-receptor type 1
- Molecular Weight
- 49966.44 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Drug created at October 21, 2016 02:53 / Updated at August 26, 2024 19:22